Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02700373 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers
A Phase 1 study of Contact Dermatitis, sponsored by Hapten Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02700373: Completed Phase 1 study of Contact Dermatitis, sponsored by Hapten Sciences.
NCT02700373 is a Phase 1 study of Contact Dermatitis that has completed, run by Hapten Sciences. The registered enrollment target is 40 participants, below the 139-participant average among 3 other Contact Dermatitis trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02700373, a Phase 1 study of Contact Dermatitis, has completed, sponsored by Hapten Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of PDC-APB by intramuscular (IM) injection compared to placebo.
Primary Outcome
The primary objective of the study is to assess the safety and tolerability of PDC-APB following single doses administered intramuscularly to healthy subjects between 18 and 55 years of age.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PDC-APB
Study Locations (1)
Tennessee
- Clinical Research Solutions - Franklin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-01 |
| Phase | Phase 1 |
What the finished NCT02700373 record still lists
NCT02700373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 139-participant average among 3 other Contact Dermatitis trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Contact Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02700373 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT02700373 about?
NCT02700373 is a clinical study titled "A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers". This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of PDC-APB by intramuscular (IM) injection compared to placebo.
What is the current status of trial NCT02700373?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-03. Estimated completion is 2018-01.
What conditions does trial NCT02700373 study?
This clinical trial studies the following conditions: Contact Dermatitis.
What interventions are being tested in trial NCT02700373?
The interventions under investigation include: Placebo (DRUG), PDC-APB (DRUG).
Who is sponsoring clinical trial NCT02700373?
This trial is sponsored by Hapten Sciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02700373 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contact Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia